|Bid||109.20 x 300|
|Ask||110.00 x 200|
|Day's range||108.68 - 110.44|
|52-week range||39.82 - 110.44|
|PE ratio (TTM)||-17.30|
|Earnings date||7 Aug 2017 - 11 Aug 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||90.36|
NEW YORK, NY / ACCESSWIRE / July 21, 2017 / Both Sarepta Therapeutics and Kite Pharma saw gains on Thursday. Kite hit a new high after highlighting positive results of an anti-CD19 chimeric antigen receptor ...
Kite Pharma, Inc. , a leading cell therapy company, highlighted the recent online publication of results in Molecular Therapy from a National Cancer Institute study of anti-CD19 chimeric antigen receptor T-cell therapy in patients with aggressive NHL including diffuse large B-cell lymphoma .
Last week an FDA advisory panel voted unanimously (10-0) to approve CTL019 (tisagenlecleucel-T), a novel CAR-T cell immunotherapy developed by Novartis (NVS), for the treatment of children and young adults (ages 3 - 25) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). B-cell ALL is a form of Leukemia (i.e.